Related Experiment Videos
[Inhaled nitric oxide: therapeutic applications in cardiac surgery]
S Estanove1, C Girard, O Bastien
1Service d'Anesthésie-Réanimation, Hôpital cardio-vasculaire et pneumologique Louis Pradel, BP Lyon-Montchat-69394 Lyon, France.
Bulletin De L'Academie Nationale De Medecine
|July 27, 2001
Summary
Inhaled nitric oxide (NO) effectively treats pulmonary arterial hypertension after cardiac surgery by dilating pulmonary arteries. Careful monitoring is advised due to potential toxicity, especially in newborns.
Area of Science:
- Cardiovascular Surgery
- Pulmonary Hypertension
- Medical Therapeutics
Context:
- Right ventricular failure is a significant postoperative risk in cardiac surgery patients with pulmonary arterial hypertension.
- Pulmonary arterial hypertension poses a major challenge in pediatric and adult cardiac surgery.
- Managing pulmonary hypertension post-cardiac surgery is critical for patient outcomes.
Purpose:
- To evaluate the efficacy and safety of inhaled nitric oxide (NO) in managing pulmonary arterial hypertension post-cardiac surgery.
- To explore the therapeutic potential of selective pulmonary vasodilation using NO.
- To establish optimal NO concentrations for postoperative cardiac surgery patients.
Summary:
- Inhaled nitric oxide (NO) selectively dilates pulmonary arteries, improving outcomes in patients with pulmonary arterial hypertension.
- Studies suggest 20 to 40 ppm NO concentrations are effective and safe for indications including mitral valve replacement, congenital heart disease correction, and heart transplantation.
- NO's mechanism involves immediate binding with hemoglobin, preserving systemic and coronary blood pressure.
Impact:
- Inhaled NO represents a fundamental therapeutic advance in managing postoperative pulmonary hypertension.
- Ensures maintenance of systemic and coronary blood pressures during treatment.
- Highlights the need for monitoring NO concentration and methaemoglobin levels due to potential toxicity, particularly in neonates.